IV期驱动基因变异非小细胞肺癌的治疗:ASCO动态指南2023.2版
本动态指南针对IV期伴驱动基因变异的非小细胞肺癌治疗,由常设专家面板持续系统检索文献并定期更新。动态指南与更新不替代治疗提供者的独立专业判断,也不考虑患者个体差异。
要点
- 动态指南针对证据快速演变、临床实践频繁变化的选定主题领域制定。
- 由常设专家面板按ASCO指南方法学手册持续系统检索健康文献并定期更新。
- 动态指南及更新不替代治疗提供者的独立专业判断,也不考虑患者个体差异。
核心结论
- 动态指南及更新不替代治疗提供者的独立专业判断,也不考虑患者个体差异。
研究设计与样本
- 本动态指南由常设专家面板按ASCO指南方法学手册持续系统检索健康文献并定期更新。
- 动态指南遵循ASCO临床实践指南利益冲突政策实施规定。
- 更新定期发布,可在https://ascopubs.org/nsclc-da-living-guideline查阅。
局限性
- 动态指南及更新不替代治疗提供者的独立专业判断,也不考虑患者个体差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline.
引用
- Owen DH, Singh N, Ismaila N, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2. J Clin Oncol. 2023. PMID: 37433095. doi:10.1200/JCO.23.01055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。